This is an excellent discussion topic. My take is less
This is an excellent discussion topic. My take is less granular. GNBT is still parent for NGIO and owns ~60% of NGIO + all decision making. How does this not carry GNBT to have a more positive pps? I do get the linear property of GNBT owning A shares, but they still own 60% of the company and have the power to unify shares at any conversion factor they choose at anytime. I would think that we would see a price alignment occur upon IPO or at least after GNBT can submit its next quarterly statement as the value of NGIO will be recognized on its balance sheet.
Current EPS = -.56
# of shares = 114.95MM
NGIO tentative valuation @ $9/share = $500MM
New asset is added to Bal Sheet at $300MM
Less current debt of $64.372MM
New asset provides positive $235,628,000 of new company value.
PPS is $2.05 at minimum.
Concerns: obv this is not yet to the $4 Nasdaq mark, abd so could still be messed with on the OTC, so it’ll be great when NGIO hits $1BB in valuation as it will easily propel GNBT to Nasdaq levels.
6
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Overview of Equity Inducement Awards Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a leading biopharmaceutical organization, has recently initiated equity inducement awards to welcome new talent to its dynamic team. This initiative demonstrates Madrigal's commitment to fostering a strong workforce geared towards tackling significant health challenges related to metabolic...
Continue Reading
Boston Metal Appoints Industry Leader Roy Harvey Boston Metal, a prominent technology company that is transforming the landscape of global metals production, has made a significant move by appointing Roy Harvey to its Board of Directors. This decision is pivotal as Boston Metal gears up for the commercial rollout of its groundbreaking Molten Oxide Electrolysis (MOE)...
Continue Reading
RBL LLC Partners with Carnrite Ventures for Biotech Growth RBL LLC, a leading biotech venture creation studio, is excited to announce a significant investment from Carnrite Ventures. This partnership aims to enhance the rapid development of their robust pipeline of innovative therapeutic companies. According to Paul Wotton, the managing partner at RBL, "Carnrite's...
Continue Reading
Introducing the OncoC4 and AcroImmune Merger OncoC4, Inc. has just announced a thrilling merger with AcroImmune, a strategic union that promises to significantly boost OncoC4's standing in the biopharmaceutical sector. This collaboration brings together two companies dedicated to pioneering advancements in cancer treatment, with a special focus on developing unique...
Continue Reading
Rezolve AI Excited About $30 Billion AI Investment Rezolve AI (NASDAQ: RZLV), well-known for its cutting-edge AI-driven commerce solutions, is enthusiastic about the recent announcement from Microsoft and BlackRock. These influential tech companies plan to invest $30 billion into AI infrastructure, a decision that could profoundly alter the landscape of the artificial...
Continue Reading
